Chargement en cours...
Bosutinib for the Treatment of Philadelphia Chromosome-Positive Leukemias
INTRODUCTION: Bosutinib is a dual ABL1 and SRC third generation tyrosine kinase inhibitor (TKI) indicated for the treatment of patients with chronic myelogenous leukemia (CML) resistant to or intolerant of other BCR-ABL1 inhibitors. Bosutinib is active against leukemia cells expressing imatinib-resi...
Enregistré dans:
| Publié dans: | Expert Opin Orphan Drugs |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2015
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6684277/ https://ncbi.nlm.nih.gov/pubmed/31388478 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1517/21678707.2015.1036027 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|